MedTrace Logo

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma.

NCT06732882 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-06-05

No results posted yet for this study

Summary

The study will investigate the Pharmacokinetic (PK), Pharmacodynamic (PD), the safety and tolerability of AZD4604, as well as to examine the effect of Fractional exhaled Nitric Oxide (FeNO) following the administration of the multiple doses of AZD4604 via Turbuhaler device.

Conditions

Interventions

DRUG

AZD4604

Participants will receive AZD4604 via Genuair/Turbuhaler device.

OTHER

Placebo

Participants will receive placebo via Genuair/Turbuhaler device.

DEVICE

Genuair

Participants will either receive AZD4604 or placebo via Genuair device.

DEVICE

Turbuhaler

Participants will receive either AZD4604 or placebo via Turbuhaler device.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-27
Primary Completion
2025-05-29
Completion
2025-05-29
FDA Drug
Yes
FDA Device
Yes

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06732882 on ClinicalTrials.gov